Relevant bibliographies by topics / Opioid use disorder (OUP)

Academic literature on the topic 'Opioid use disorder (OUP)'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Opioid use disorder (OUP).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Opioid use disorder (OUP)"

1

Edinoff, Amber N., Catherine A. Nix, Claudia V. Orellana, Samantha M. StPierre, Erin A. Crane, Blaine T. Bulloch, Elyse M. Cornett, et al. "Naltrexone Implant for Opioid Use Disorder." Neurology International 14, no. 1 (December 30, 2021): 49–61. http://dx.doi.org/10.3390/neurolint14010004.

Full text
Abstract:
The continued rise in the availability of illicit opioids and opioid-related deaths in the United States has left physicians, researchers, and lawmakers desperate for solutions to this ongoing epidemic. The research into therapeutic options for the treatment of opioid use disorder (OUD) began with the introduction of methadone in the 1960s. The approval of oral naltrexone initially showed much promise, as the drug was observed to be highly potent in antagonizing the effects of opioids while producing no opioid agonist effects of its own and having a favorable side effect profile. Patients that routinely take their naltrexone reported fewer days of heroin use and had more negative drug tests than those without treatment. Poor outcomes in OUD patients treated with naltrexone have been directly tied to short treatment time. Studies have shown that naltrexone given orally vs. as an implant at the 6-month interval showed a higher non-compliance rate among those who used oral medications at the 6-month mark and a slower return to use rate. There were concerns that naltrexone could possibly worsen negative symptoms seen in opiate use disorder related to blockade of endogenous opioids that are important for pleasurable stimuli. Studies have shown that naltrexone demonstrated no increase in levels of anxiety, depression and anhedonia in participants and another study found that those treated with naltrexone had a significant reduction in mental health-related hospitalizations. The latter study also concluded that there was no increased risk for mental health-related incidents in patients taking naltrexone via a long-acting implant. Although not yet FDA approved in the United States, naltrexone implant has shown promising results in Europe and Australia and may provide a novel treatment option for opioid addiction.
APA, Harvard, Vancouver, ISO, and other styles
2

Talmage, James B. "Rating Opioid Use Disorder for Permanent Impairment." Guides Newsletter 25, no. 1 (January 1, 2020): 3–11. http://dx.doi.org/10.1001/amaguidesnewsletters.2020.janfeb01.

Full text
Abstract:
Abstract The duration of opioid therapy after surgery is the strongest known predictor of ultimate misuse, and researchers have reported that the number of days for which medication was prescribed and the total number of postoperative prescriptions each predicts long-term use. This article addresses the question of rating the impairment for an individual with no history of substance use disorder before a work injury, who is prescribed opioids for this injury, and who subsequently develops opioid use disorder (OUD). The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, should be used in conjunction with the AMA Guides to the Evaluation of Permanent Impairment, (AMA Guides), Sixth Edition. A person who is prescribed opioids is not yet at maximum medical improvement (MMI) and cannot be rated. Referral for substantiation of the diagnosis and for initiation of treatment are necessary before OUD is confirmed and the patient is at MMI. The AMA Guides is based on impairments of activities of daily living (ADL), so a patient's MMI should result in a happy outcome and no impairment, although the burden of treatment compliance may be a relevant consideration. The article concludes with an extensive literature review, including abstracts of published articles regarding OUD in various settings.
APA, Harvard, Vancouver, ISO, and other styles
3

Patel, Biren, and Thomas R. Kosten. "Keeping Up with Clinical Advances: Opioid Use Disorder." CNS Spectrums 24, S1 (July 10, 2019): 14–24. http://dx.doi.org/10.1017/s109285291900110x.

Full text
Abstract:
Opioid use disorder (OUD) is a disorder that can lead to several negative outcomes, including overdose and death. A variety of opioids can be abused by individuals including both prescribed and non-prescribed opioids. Continued opioid use can be driven by negative affective states associated with opioid withdrawal. Several treatments exist in the field including medication assisted treatments such as methadone, buprenorphine, and naltrexone. Treatments such as clonidine and lofexidine can also be used to assist with decreasing withdrawal symptoms. Increasing adherence to treatment can further improve patient outcomes and promote continuation with treatment. A variety of methods to reduce relapse can also be utilized such as opioid agonists and maintenance therapy. According to the Centers for Disease Control, opioid overdoses contributed to 67.8% of overdose deaths in 2017.
APA, Harvard, Vancouver, ISO, and other styles
4

Koehl, Jennifer L., David E. Zimmerman, and Patrick J. Bridgeman. "Medications for management of opioid use disorder." American Journal of Health-System Pharmacy 76, no. 15 (July 18, 2019): 1097–103. http://dx.doi.org/10.1093/ajhp/zxz105.

Full text
Abstract:
Abstract Purpose The use of buprenorphine, methadone, and long-acting naltrexone for treatment of opioid use disorder (OUD) is discussed, including a review of current literature detailing treatment approaches and action steps to optimize treatment in acute care and office-based settings. Summary The U.S. epidemic of opioid-related deaths has been driven by misuse of prescription opioids and, increasingly, illicit drugs such as heroin, fentanyl, and fentanyl analogs, necessitating a refocusing of treatment efforts on expanding access to life-saving, evidence-based OUD pharmacotherapy. Inpatient treatment of opioid withdrawal includes acute symptom control through a combination of nonopioid medications and long-term pharmacotherapy to lessen opioid craving and facilitate stabilization and recovery. Methadone and buprenorphine reduce opioid craving, increase treatment retention, reduce illicit opioid use, and increase overall survival. Buprenorphine has logistical advantages over methadone, such as greater flexibility of treatment setting and less risk of adverse effects. Studies have shown the efficacy of long-acting injectable naltrexone to be comparable to that of buprenorphine if patients are detoxified prior to initiation of therapy; however, patients with active OUD are often not able to complete the week-long period of opioid abstinence needed prior to initiation of naltrexone injections. Although buprenorphine is preferred by many patients and can be prescribed in office-based settings, there remains a paucity of physicians certified to prescribe it. Conclusion Buprenorphine has become the medication of choice for many patients with OUD, but its use is limited by the low number of physicians certified to prescribe the agent. Other agents studied for treatment of OUD include methadone and naltrexone.
APA, Harvard, Vancouver, ISO, and other styles
5

Daoust, R., J. Paquet, L. Moore, A. Cournoyer, M. Emond, S. Gosselin, G. Lavigne, A. Boulanger, J. Mac-Thiong, and J. Chauny. "LO91: Opioid poisoning and opioid use disorder in older trauma patients." CJEM 22, S1 (May 2020): S40—S41. http://dx.doi.org/10.1017/cem.2020.145.

Full text
Abstract:
Introduction: Patients hospitalized following a trauma will be frequently treated with opioids during their stay and after discharge. We examined the relationship between acute phase (< 3 months) opioid use after discharge and the risk of opioid poisoning (OP) or opioid use disorder (OUD) in older trauma patients Methods: In a retrospective multicenter cohort study conducted on registry data, we included all patients aged 65 years and older admitted (hospital stay >2 days) for injury in 57 trauma centers in the province of Quebec (Canada) between 2004 and 2014. We searched for OP and OUD from ICD-9 and ICD-10 code diagnosis that resulted in a hospitalization or a medical consultation after their initial injury. Patients that filled an opioid prescription within a 3-month period after sustaining the trauma were compared to those who did not fill an opioid prescription during that period using Cox proportional hazards regressions. Results: A total of 70,314 participants were retained for analysis; median age was 82 years (IQR: 75-87), 68% were women, and 34% of the patients filled an opioid prescription within 3-months of the initial trauma. During a median follow-up of 2.6 years (IQR: 1-5), 192 participants (0.30%; 95%CI: 0.25%-0.35%) were hospitalized for OP and 73 (0.10%; 95%CI: 0.07%-0.13%) were diagnosed with OUD. Having filled an opioid prescription within 3-months of injury was associated with an increased hazard ratio of OP (2.6; 95%CI: 1.9-3.5) and OUD (4.0; 95%CI: 2.3-7.0). However, history of OP (2.7; 95%CI: 1.2-6.1), of substance use disorder (4.3; 95%CI: 2.4-7.9), or of opioid prescription filled (2.7; 95%CI: 2.1-3.5) before trauma were also related to OP or OUD. Conclusion: Opioid poisoning and opioid use disorder are rare events after hospitalization for trauma in older patients. However, opioids should be used cautiously in patients with history of substance use disorder, opioid poisoning or opioid use during the past year.
APA, Harvard, Vancouver, ISO, and other styles
6

Hall, Elizabeth A., Alina Cernasev, Umida Nasritdinova, Michael P. Veve, and Kenneth C. Hohmeier. "Stigma of Opioid Use Disorder and Its Indirect Effects on Student Pharmacists’ Perceptions and Attitudes." Pharmacy 8, no. 3 (August 14, 2020): 144. http://dx.doi.org/10.3390/pharmacy8030144.

Full text
Abstract:
Objectives: Pharmacists play a vital role in serving patients during the ongoing nationwide opioid epidemic, and so it is also critical to educate the next generation of pharmacists on opioids and opioid use disorder (OUD). The primary objective of this study was to quantitatively characterize student perceptions of opioid use and the stigma associated with OUD. Secondary aims were to determine whether differences in perceptions exist based upon the student’s year in the Doctor of Pharmacy program or employment in a community pharmacy. Methods: First-, second-, third-, and fourth-year student pharmacists voluntarily completed an electronic survey regarding perceptions of opioid use and stigma associated with OUD. Results: Of the 9 survey items, students were most uncomfortable referring patients to community resources for addiction support and/or treatment (25.3% comfortable or very comfortable). Students working in a community pharmacy were significantly more comfortable talking to patients attempting to refill opioids early and providing opioid counseling as compared to their peers not working in community pharmacy. Fourth-year students reported a higher level of comfort talking to a patient attempting to refill an opioid prescription early, counseling a patient on an opioid prescription, and providing information about alternatives to opioids. Third-year students responded most favorably to the items regarding how well the curriculum has prepared them to interact with patients taking opioids and those with OUD. Conclusions: These findings reveal that students are comfortable counseling on opioids and discussing alternative options. Differences in perceptions were observed based upon the student’s year in the program and whether or not they were employed in a community pharmacy setting.
APA, Harvard, Vancouver, ISO, and other styles
7

Zhou, Kehua, Peng Jia, Swati Bhargava, Yong Zhang, Taslima Reza, Yuan Bo Peng, and Gary G. Wang. "Opioid tapering in patients with prescription opioid use disorder: A retrospective study." Scandinavian Journal of Pain 17, no. 1 (October 1, 2017): 167–73. http://dx.doi.org/10.1016/j.sjpain.2017.09.005.

Full text
Abstract:
AbstractBackground and aimsOpioid use disorder (OUD) refers to a maladaptive pattern of opioid use leading to clinically significant impairment or distress. OUD causes, and vice versa, misuses and abuse of opioid medications. Clinicians face daily challenges to treat patients with prescription opioid use disorder. An evidence-based management for people who are already addicted to opioids has been identified as the national priority in the US; however, options are limited in clinical practices. In this study, we aimed to explore the success rate and important adjuvant medications in the medication assisted treatment with temporary use of methadone for opioid discontinuation in patients with prescription OUD.MethodsThis is a retrospective chart review performed at a private physician office for physical medicine and rehabilitation. We reviewed all medical records dated between December 1st, 2011 and August 30th, 2016. The initial evaluation of the included patients (N =140) was completed between December 1st, 2011 and December 31st, 2014. They all have concumittant prescription OUD and chronic non-cancer pain. The patients (87 female and 53 male) were 46.7 ± 12.7 years old, and had a history of opioid use of 7.7 ±6.1 years. All patients received the comprehensive opioid taper treatments (including interventional pain management techniques, psychotherapy, acupuncture, physical modalities and exercises, and adjuvant medications) on top of the medication assisted treatment using methadone (transient use). Opioid tapering was considered successful when no opioid medication was used in the last patient visit.ResultsThe 140 patients had pain of 9.6 ± 8.4 years with 8/10 intensity before treatment which decreased after treatment in all comparisons (p < 0.001 for all). Opioids were successfully tapered off in 39 (27.9%) patients after 6.6 ±6.7 visits over 8.8 ±7.2 months; these patients maintained opioid abstinence over 14.3 ± 13.0 months with regular office visits. Among the 101 patients with unsuccessful opioid tapering, 13 patients only visited the outpatient clinic once. Significant differences were found between patients with and without successful opioid tapering in treatment duration, number of clinic visits, the use of mirtazepine, bupropion, topiramate, and trigger point injections with the univariate analyses. The use of mirtazepine (OR, 3.75; 95% CI, 1.48–9.49), topiramate (OR, 5.61; 95% CI, 1.91–16.48), or bupropion (OR, 2.5; 95% CI, 1.08–5.81) was significantly associated with successful opioid tapering. The associations remain significant for mirtazepine and topiramate (not bupropion) in different adjusted models.ConclusionsWith comprehensive treatments, 27.9% of patients had successful opioid tapering with opioid abstinence for over a year. The use of mirtazepine, topiramate, or likely bupropion was associated with successful opioid tapering in the medication assisted treatment with temporary use of methadone. Opioid tapering may be a practical option and should be considered for managing prescription OUD.ImplicationsFor patients with OUD, indefinite opioid maintenance treatment may not be necessary. Considering the ethical values of autonomy, nonmaleficence, and beneficence, clinicians should provide patients with OUD the option of opioid tapering.
APA, Harvard, Vancouver, ISO, and other styles
8

Herrera, S., A. Riquelme, T. León, and M. Babul. "Demographic characteristics, medical and psychiatric history of patients with prescription opioid use disorder." European Psychiatry 33, S1 (March 2016): S300—S301. http://dx.doi.org/10.1016/j.eurpsy.2016.01.1025.

Full text
Abstract:
IntroductionOver the past two decades the prescription of opioid analgesics has increased with a subsequent escalating in prescription opioid misuse. It is estimated that 4.5 million (2.5%) of the United States of America population abuse of pain relievers; opioids are among the most commonly.In Chile there are few reports about the prevalence of opioid use disorder.ObjectivesThe aim of this study is to describe the demographic characteristics, medical and psychiatric comorbidity of patients that suffer from opioid addiction.Patients and methodsThis transversal study examined data of 7 patients with opioid use disorder (OUD; DSM-5) that consulted at the addiction unit of “Red de Salud, Pontificia Universidad Católica de Chile”, between November 2013 and October 2015. Data included: demographics, medical and psychiatric history, laboratory and imaging tests.ResultsOf all the patients, 57% were men, 25 to 67 years of age, 43% between 35-40 years; 57% were married; 57% had completed studies at university. 43% had also alcohol use disorder, 28% marijuana, 28% cocaine and 28% benzodiazepines than in most cases began before OUD. In addition; 57% had medical comorbidity among which stand out obesity (17%), osteoarthritis (17%) and chronic low back pain (17%). Eighty-three percent require hospitalization. Twenty-eight percent had abnormal liver tests and one patient had positive hepatitis B core antibody. Opioids used were: morphine(14%), codeine (43%), tramadol (42%).ConclusionThese results emphasize on the misuse of prescription opioids analgesics, the complexity of patients with OUD and the prevalence of other substance use disorder that precedes and accompany OUD.Disclosure of interestThe authors have not supplied their declaration of competing interest.
APA, Harvard, Vancouver, ISO, and other styles
9

Nguyen, Thomas A., Jennie H. Hahn, and Stephen M. Strakowski. "Pharmacotherapies for treating opioid use disorder." CNS Spectrums 18, no. 6 (April 8, 2013): 289–95. http://dx.doi.org/10.1017/s1092852913000229.

Full text
Abstract:
Opioid use disorder (OUD) is a major public health problem in the United States. It has resulted in devastating consequences for people with this condition, including psychosocial and legal problems, in addition to contraction of infectious diseases such as HIV and hepatitis B and C. Furthermore, this disease can cause fatalities from drug overdoses and drug–drug interactions. OUD shatters families and destroys relationships. Effective treatment is crucial in order to curtail the consequences of this condition. The objective of this article is to provide a review of the pharmacotherapies currently being used to treat OUD.
APA, Harvard, Vancouver, ISO, and other styles
10

Tewary, Sweta, Ariel Kidron, Naushira Pandya, Jim Howell, Marie Florent-Caree, Annisah Ishmael, and Rebecca Cherner. "Understanding Medical Students’ Knowledge of Opioid Use Disorder: A Preliminary Study." Innovation in Aging 4, Supplement_1 (December 1, 2020): 219. http://dx.doi.org/10.1093/geroni/igaa057.706.

Full text
Abstract:
Abstract The rise of the opioid epidemic over the last two decades has increased the mortality rate, healthcare cost, and drug overdose deaths across the country. Practicing physicians are lacking in education regarding non-opioid alternatives to pain management, prevention, diagnosis, and treatment of opioid use disorder (OUD). Existing literature suggest a link between knowledge discrepancy and opioid use among clinicians resulting in patient’s abuse of opioids. Therefore, it is important to educate medical students at the start of their career. This preliminary study assesses the current knowledge and perceived skills of medical students regarding (OUD)/opioid misuse and related content in order to identify gaps and provide necessary education. The study used a pre-post survey method to understand the demographics, medical, and clinical knowledge about opioid use, abuse, and clinical knowledge regarding patient opioid overdose. The self-administered survey was administered to all students 18 years or older, M1- M4 enrolled in NSU-KPCOM. A total of 1164 students met these criteria. However, only 137 students participated in the Pre-survey collected from August 2019 to September 2019. Approximately 12% of the eligible students participated in the pre-survey. Data was analyzed using frequencies and percentages. Results of the pre-survey suggest a progressive increase in opioid knowledge from M1 to M4 years. Results of the study suggest investigating a relationship between medical education and knowledge of opioid usage, with a specific lens aimed at assessing the efficacy of opioid education during second and third years of medical school
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Opioid use disorder (OUP)"

1

Wu, Katherine C. "A Care and Justice Ethics Approach to Opioid Use Disorder in Pregnancy." NEOMED College of Graduate Studies / OhioLINK, 2021. http://rave.ohiolink.edu/etdc/view?acc_num=ne2gs1620579941339304.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hayel-Moghadam, Kamran, and Meredith K. Ginley. "The Interplay between Depression and Bipolar Disorders and OUD/SUD." Digital Commons @ East Tennessee State University, 2021. https://dc.etsu.edu/etsu-works/8880.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mort, Sophia C. "Utilizing Health Professional Students’ Knowledge, Attitudes, and Beliefs to Inform the Development of a Contact-Based Educational Approach to Address the Opioid Epidemic." Ohio University / OhioLINK, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=ohiou1597412295795281.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Pack, Robert P. "Opioid Use Disorder." Digital Commons @ East Tennessee State University, 2017. https://dc.etsu.edu/etsu-works/1335.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Creviston, Megan. "Adverse Childhood Experiences among Individuals with Opioid Use Disorder." Wright State University / OhioLINK, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=wright1610112137970568.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Drayton, Antwana L. "Opioid Use Disorder: The Ugly Return and Treatment Effectiveness of Heroin Use." UNF Digital Commons, 2018. https://digitalcommons.unf.edu/etd/814.

Full text
Abstract:
Relationships among demographic, socioeconomic and person factors and Opioid Use Disorder diagnosis, treatment, and recidivism were explored. Data from a sample of 4,860 adults with substance use difficulties were analyzed. A program evaluation was conducted on Gateway Community Services to explore the use of Medication Assisted Treatments (MATs) and Psychosocial (PS) treatments to address Opioid Use Disorder. Using archival data, a chi-square analysis and independent sample t-test was performed. The results expressed that a relationship among race, type of substance use diagnosis, and treatment type and recidivism rate was found. While White/Non-Hispanics adults were more likely to use heroin than any other racial/ethnic backgrounds, gender differences were also found. Finally, frequency and duration of a combined treatment (PS + MAT) were negatively related to recidivism with no determination of previous prescription opioid use to be examined at this time. Keywords: medication assisted treatment, recidivism, psychosocial, opioid
APA, Harvard, Vancouver, ISO, and other styles
7

Ochalek, Taylor Anne. "Examining sucrose subjective response among individuals with opioid use disorder." ScholarWorks @ UVM, 2020. https://scholarworks.uvm.edu/graddis/1185.

Full text
Abstract:
Aims: Opioid use disorder (OUD) is associated with significant morbidity and mortality, and opioid agonist treatment (OAT) with methadone or buprenorphine represents the most efficacious treatment. However, data suggest that chronic administration of opioids may be associated with significant weight gain, possibly by altering an organism’s perception of and preference for sweet foods. The primary aim of this laboratory study was to rigorously examine sucrose subjective response among adults receiving OAT and a comparison sample without OUD. As secondary outcomes, we also sought to compare the groups on additional baseline characteristics that may influence subjective sucrose response and weight gain during treatment. Methods: Participants were 40 adults receiving treatment for OUD (OUD+) and a comparison sample of 40 adults without OUD (OUD-). All participants completed an initial screening visit that included questionnaires on eating behaviors, diet and nutrition, recent substance use, and measurement of body mass index. Eligible participants completed two, same-day outpatient laboratory sessions during which they sampled six experimenter-administered concentrations of sucrose solution (0, 0.1, 0.25, 0.5, 0.75, and 1.0M in distilled water) each three times under double-blind counterbalanced conditions. Following each exposure, participants rated the pleasantness and intensity of each sample using 100-point visual analog scales. Results: OUD+ participants rated sucrose solutions as less pleasant than OUD- participants (p<0.001). However, this effect was limited to the three lowest sucrose concentrations (0, 0.1, 0.25M), and at higher concentrations there were no group differences. There were no between-group differences on ratings of intensity (p=0.35). Given these baseline group differences in placebo (0M) responding, sucrose response was also examined in terms of change from baseline. In this analysis, there was a significant group effect, with a higher magnitude of change in pleasantness ratings and a lower magnitude of change in intensity ratings from 0M in OUD+ vs. OUD- participants (p’s<0.05). With regard to baseline characteristics that may influence sucrose response and eating behavior more generally, the OUD+ group had a higher prevalence of obesity, food insecurity, unhealthy eating behaviors, high sugar consumption, and nutrition knowledge deficits compared to the OUD- group (p’s<0.05). Conclusion: Data from preclinical and clinical research have suggested that opioid agonist medications may enhance subjective response to sweet flavors. In the present study, OUD+ participants exhibited a higher magnitude of change in pleasantness ratings from placebo compared to OUD- participants. However, this effect was largely driven by pronounced group differences in perceived pleasantness of essentially unsweet solutions. On the outcome of sucrose intensity, findings were more mixed with no consistent differences between OUD+ and OUD- participants. In contrast, group differences were far more pronounced in participants’ daily eating behaviors and nutrition knowledge, with OUD+ participants presenting with a consistently more severe profile. These data highlight the significant risk factors experienced by OUD+ individuals that extend beyond drug-related risks and may inform future scientific and clinical efforts to improve health outcomes in this vulnerable population.
APA, Harvard, Vancouver, ISO, and other styles
8

Toler, Kimberly. "Trauma-€Informed Care for Persons With Opioid Use Disorder in Ohio." ScholarWorks, 2019. https://scholarworks.waldenu.edu/dissertations/7202.

Full text
Abstract:
Prevention, social work, and community awareness programs have not led to the successful reduction of opioid overdose deaths nationwide, and particularly in Ohio. This study explored social work perspectives about trauma-€informed care (TIC) for persons with opioid use disorder in Ohio. The research questions for this study examined how social workers in Ohio implemented TIC when providing outpatient treatment to opioid users and what challenges they faced when providing TIC. Using an action research methodology, data were collected through individual semistructured interviews with 5 social work professionals, selected through purposive sampling based on experience in the field of substance use in Ohio and the use of TIC. Contemporary trauma theory and TIC were chosen to frame the research project. Three themes emerged through thematic analysis of the data: appreciation for trauma-€informed opioid use disorder treatment, organizational and professional challenges to the use of trauma-€informed opioid use disorder treatment, and environmental barriers to successful trauma-€informed outpatient opioid use disorder programming. The study aligned with the social work core values of competence and principles of harm reduction. The findings from the study might bring about social change by igniting dialogue among treatment providers about how TIC interventions could support integrated treatment and holistic approaches to combatting opioid addiction in Ohio.
APA, Harvard, Vancouver, ISO, and other styles
9

Salwan, Aaron J., Nicholas E. Hagemeier, Kelly N. Foster, Jesse Arnold, Billy Brooks, Arsham Alamian, and Robert P. Pack. "Pharmacist and Physician Engagement in Tertiary Prevention of Opioid Use Disorder." Digital Commons @ East Tennessee State University, 2019. https://dc.etsu.edu/etsu-works/7742.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bogdanowicz, Karolina. "Risk of mortality in secondary mental health treatment for opioid use disorder." Thesis, King's College London (University of London), 2017. https://kclpure.kcl.ac.uk/portal/en/theses/risk-of-mortality-in-secondary-mental-health-treatment-for-opioid-use-disorder(37f04662-37c8-4a28-8247-bd3b0b55e3e8).html.

Full text
Abstract:
This thesis utilizes anonymized patient health records from one of the largest mental health service providers in Europe and explores mortality risk factors, at both patient-level and service-level, in individuals with opioid use disorder (OUD) enrolled in secondary drug and alcohol treatment. The thesis explores associations between psychological wellbeing, comorbid diagnosis of personality disorder (PD), serious mental illness (SMI) and alcohol use disorder (AUD), in relation to mortality in opioid dependence. Specific risk situations in time and context are also explored, with investigations of clustering of deaths in the period immediately after transfer of patients and their care and after end of opioid substitution treatment (OST) in a cohort of opioid dependent individuals in specialist addiction treatment. The thesis also investigates if routine brief risk assessments given to OUD patients can predict all-cause or cause specific mortality and determine if these risks may be modified by admission to services.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Opioid use disorder (OUP)"

1

Bain, Lisa, Sheena M. Posey Norris, and Clare Stroud, eds. Methadone Treatment for Opioid Use Disorder. Washington, D.C.: National Academies Press, 2022. http://dx.doi.org/10.17226/26635.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Leshner, Alan I., and Michelle Mancher, eds. Medications for Opioid Use Disorder Save Lives. Washington, D.C.: National Academies Press, 2019. http://dx.doi.org/10.17226/25310.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Nicholson, Anna, ed. Medication-Assisted Treatment for Opioid Use Disorder. Washington, D.C.: National Academies Press, 2018. http://dx.doi.org/10.17226/25322.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wakeman, Sarah E., and Josiah D. Rich, eds. Treating Opioid Use Disorder in General Medical Settings. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-80818-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Matthews, Annette M., and Jonathan C. Fellers, eds. Treating Comorbid Opioid Use Disorder in Chronic Pain. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-29863-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Nicholson, Anna, ed. Integrating Responses at the Intersection of Opioid Use Disorder and Infectious Disease Epidemics. Washington, D.C.: National Academies Press, 2018. http://dx.doi.org/10.17226/25153.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Graig, Laurene, India Olchefske, and Joe Alper, eds. Pain Management for People with Serious Illness in the Context of the Opioid Use Disorder Epidemic. Washington, D.C.: National Academies Press, 2019. http://dx.doi.org/10.17226/25435.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Brunner, Emily, and Robert Levy. The Epidemiology of Pain and Addiction (DRAFT). Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190265366.003.0001.

Full text
Abstract:
The chapter on the epidemiology of pain and addiction opens with a discussion of epidemiological principles and then proceeds to review two categories of data: that which are available on the use of opioids to treat chronic pain, and that reflecting opioid use disorder (OUD). The data are provided with graphical representations that may aid in discussions and in teaching. An accompanying glossary of epidemiological terminology facilitates understanding of the data. Conclusions are drawn from the prevalence of use and of mortality that contribute to an understanding of the origins and direction of the opioid use crisis. An accompanying text box provides resources for further exploration of the topics discussed in the chapter.
APA, Harvard, Vancouver, ISO, and other styles
9

Harvard Medical School Center for Global Health Delivery. Opioid Use Disorder Around the Globe. Center for Global Health Delivery-Dubai, 2021.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Board on Health Sciences Policy, National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Committee on Medication-Assisted Treatment for Opioid Use Disorder, and Michelle Mancher. Medications for Opioid Use Disorder Save Lives. National Academies Press, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Opioid use disorder (OUP)"

1

Mallick-Searle, Theresa. "Opioids and Opioid Use Disorder (OUD) in Pregnancy." In Holistic Pain Management in Pregnancy, 27–31. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-06322-0_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Maier, Craig T. "Opioid Use Disorder." In Participatory Community Inquiry in the Opioid Epidemic, 8–21. New York: Routledge, 2021. http://dx.doi.org/10.4324/9781003243663-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ferguson, Sierra, and Aviva Teitelbaum. "Opioid Use Disorder." In Psychiatry Update, 67–79. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-86430-9_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Shoukry, Alfred, and Melissa A. McNeil. "Opioid Use Disorder." In Sex- and Gender-Based Women's Health, 485–93. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-50695-7_32.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bawor, Monica, Brittany Dennis, James MacKillop, and Zainab Samaan. "Opioid Use Disorder." In Integrating Psychological and Pharmacological Treatments for Addictive Disorders, 124–49. New York, NY : Routledge, 2017. |: Routledge, 2017. http://dx.doi.org/10.4324/9781315683331-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Donald, Rebecca, and David Marcovitz. "Case 14: Opioid Use Disorder." In Hospitalized Chronic Pain Patient, 127–38. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-08376-1_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Blessing, Esther, Sanya Virani, and John Rotrosen. "Clinical Trials for Opioid Use Disorder." In Substance Use Disorders, 167–202. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/164_2019_304.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wakeman, Sarah E. "Harm Reduction Approaches for Opioid Use Disorder." In Treating Opioid Addiction, 169–80. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16257-3_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Renner, John A., and Mitchell B. Crawford. "Medication for the Treatment of Opioid Use Disorder." In Treating Opioid Addiction, 89–107. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16257-3_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Unger, Annemarie, and Gabriele Fischer. "Opioid Use Disorder and Its Treatment." In Encyclopedia of Psychopharmacology, 1169–76. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-36172-2_261.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Opioid use disorder (OUP)"

1

Wadekar, Adway. "Predicting Opioid Use Disorder (OUD) Using A Random Forest." In 2019 IEEE 43rd Annual Computer Software and Applications Conference (COMPSAC). IEEE, 2019. http://dx.doi.org/10.1109/compsac.2019.00161.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sawin, Gregory, Truls Ostbye, Sara Mazzarelli, Gabriela Plasencia, Lauren Hart, and Audrey Blewer. "Exploring barriers and facilitators for starting MAT for Opioid Use Disorder (OUD) in a family medicine residency clinic." In NAPCRG 49th Annual Meeting — Abstracts of Completed Research 2021. American Academy of Family Physicians, 2022. http://dx.doi.org/10.1370/afm.20.s1.2850.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ranapurwala, S., I. Alam, M. Clark, T. Carey, P. Chelminski, B. Pence, J. Korte, et al. "0108 Limitations of opioid use disorder (OUD) ICD codes: development and validation of a new OUD identification algorithm in electronic medical records." In Injury and Violence Prevention for a Changing World: From Local to Global: SAVIR 2021 Conference Abstracts. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/injuryprev-2021-savir.81.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

McDougall, Sarah, Priyanka Annapureddy, Praveen Madiraju, Nicole Fumo, and Stephen Hargarten. "Predicting Opioid Overdose Readmission and Opioid Use Disorder with Machine Learning." In 2020 IEEE International Conference on Big Data (Big Data). IEEE, 2020. http://dx.doi.org/10.1109/bigdata50022.2020.9378496.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

"CHARACTERIZING THE CLINICAL LANGUAGE OF OPIOID USE DISORDER." In 15th International Conference on ICT, Society and Human Beings (ICT 2022), the 19th International Conference Web Based Communities and Social Media (WBCSM 2022) and 14th International Conference on e-Health (EH 2022). IADIS Press, 2022. http://dx.doi.org/10.33965/ict_wbc_eh2022_202204l026.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"IDENTIFYING AND UNDERSTANDING OPIOID USE DISORDER IN CLINICAL NOTES." In 12th International Conference on e-Health. IADIS Press, 2020. http://dx.doi.org/10.33965/eh2020_202009l018.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tas, B., N. J. Kalk, M. Lozano- García, G. F. Rafferty, P. S. P. Cho, M. Kelleher, J. Moxham, J. Strang, and C. Jolley. "Risk factors for respiratory depression in Opioid Use Disorder." In ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.2791.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Li, S., N. Sharma, D. C. Kazmierski, Y. Wang, K. Shah, H. Thyagaturu, K. Yang, and P. O. Ochieng. "Opioid Use Disorder in Systemic Candidiasis a Ten-Year Analysis." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3864.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kilby, Angela E. "Algorithmic Fairness in Predicting Opioid Use Disorder using Machine Learning." In FAccT '21: 2021 ACM Conference on Fairness, Accountability, and Transparency. New York, NY, USA: ACM, 2021. http://dx.doi.org/10.1145/3442188.3445891.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Shankar, D., K. Oleinik, R. Seibert, V. Cobb, Z. Weinstein, B. Borrelli, L. Quintiliani, et al. "Addressing Barriers to Quitting Cigarettes Among Patients with Opioid Use Disorder." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2999.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Opioid use disorder (OUP)"

1

Zullo, Andrew R., Kristin J. Danko, Patience Moyo, Gaelen P. Adam, Melissa Riester, Hannah J. Kimmel, Orestis A. Panagiotou, Francesca L. Beaudoin, Daniel Carr, and Ethan M. Balk. Prevention, Diagnosis, and Management of Opioids, Opioid Misuse, and Opioid Use Disorder in Older Adults. Agency for Healthcare Research and Quality (AHRQ), November 2020. http://dx.doi.org/10.23970/ahrqepctb37.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Barrette, Eric, Leemore Dafny, and Karen Shen. Do Policies to Increase Access to Treatment for Opioid Use Disorder Work? Cambridge, MA: National Bureau of Economic Research, July 2021. http://dx.doi.org/10.3386/w29001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Priest, Kelsey. Hospital-Based Services for Opioid Use Disorder: A Study of Supply-Side Attributes. Portland State University Library, January 2000. http://dx.doi.org/10.15760/etd.6705.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Burke, Mary A., Riley Sullivan, Katherine Carman, Hefei Wen, J. Frank Wharam, and Hao Yu. Employment Trajectories among Individuals with Opioid Use Disorder: Can Evidence-Based Treatment Improve Outcomes? Federal Reserve Bank of Boston, December 2022. http://dx.doi.org/10.29412/res.wp.2022.25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Chan, Brian, Emily Gean, Irina Arkhipova-Jenkins, Jennifer Gilbert, Jennifer Hilgart, Celia Fiordalisi, Kimberly Hubbard, et al. Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder: A Rapid Evidence Review. Agency for Healthcare Research and Quality (AHRQ), July 2020. http://dx.doi.org/10.23970/ahrqepcrapidmat.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Jones, Kristal, Brandn Green, Katie Loveland, and Tabitha Stickel. Access to Opioid Use Disorder Treatment for Pregnant and Postpartum Women: Challenges, Barriers and Opportunities in Montana. JG Research and Evaluation, 2021. http://dx.doi.org/10.36855/sor2021.2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Green, Brandn, Kirsten Smith, Anna Schmitt, and Kirsten Krane. The role of stigma in referrals for medication for opioid use disorder: Three case studies in Montana. JG Research and Evaluation, 2021. http://dx.doi.org/10.36855/sor2021.3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Chou, Roger, Jesse Wagner, Azrah Y. Ahmed, Ian Blazina, Erika Brodt, David I. Buckley, Tamara P. Cheney, et al. Treatments for Acute Pain: A Systematic Review. Agency for Healthcare Research and Quality (AHRQ), December 2020. http://dx.doi.org/10.23970/ahrqepccer240.

Full text
Abstract:
Objectives. To evaluate the effectiveness and comparative effectiveness of opioid, nonopioid pharmacologic, and nonpharmacologic therapy in patients with specific types of acute pain, including effects on pain, function, quality of life, adverse events, and long-term use of opioids. Data sources. Electronic databases (Ovid® MEDLINE®, PsycINFO®, Embase®, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews) to August 2020, reference lists, and a Federal Register notice. Review methods. Using predefined criteria and dual review, we selected randomized controlled trials (RCTs) of outpatient therapies for eight acute pain conditions: low back pain, neck pain, other musculoskeletal pain, neuropathic pain, postoperative pain following discharge, dental pain (surgical or nonsurgical), pain due to kidney stones, and pain due to sickle cell disease. Meta-analyses were conducted on pharmacologic therapy for dental pain and kidney stone pain, and likelihood of repeat or rescue medication use and adverse events. The magnitude of effects was classified as small, moderate, or large using previously defined criteria, and strength of evidence was assessed. Results. One hundred eighty-three RCTs on the comparative effectiveness of therapies for acute pain were included. Opioid therapy was probably less effective than nonsteroidal anti-inflammatory drugs (NSAIDs) for surgical dental pain and kidney stones, and might be similarly effective as NSAIDs for low back pain. Opioids and NSAIDs were more effective than acetaminophen for surgical dental pain, but opioids were less effective than acetaminophen for kidney stone pain. For postoperative pain, opioids were associated with increased likelihood of repeat or rescue analgesic use, but effects on pain intensity were inconsistent. Being prescribed an opioid for acute low back pain or postoperative pain was associated with increased likelihood of use of opioids at long-term followup versus not being prescribed, based on observational studies. Heat therapy was probably effective for acute low back pain, spinal manipulation might be effective for acute back pain with radiculopathy, acupressure might be effective for acute musculoskeletal pain, an opioid might be effective for acute neuropathic pain, massage might be effective for some types of postoperative pain, and a cervical collar or exercise might be effective for acute neck pain with radiculopathy. Most studies had methodological limitations. Effect sizes were primarily small to moderate for pain, the most commonly evaluated outcome. Opioids were associated with increased risk of short-term adverse events versus NSAIDs or acetaminophen, including any adverse event, nausea, dizziness, and somnolence. Serious adverse events were uncommon for all interventions, but studies were not designed to assess risk of overdose, opioid use disorder, or long-term harms. Evidence on how benefits or harms varied in subgroups was lacking. Conclusions. Opioid therapy was associated with decreased or similar effectiveness as an NSAID for some acute pain conditions, but with increased risk of short-term adverse events. Evidence on nonpharmacological therapies was limited, but heat therapy, spinal manipulation, massage, acupuncture, acupressure, a cervical collar, and exercise were effective for specific acute pain conditions. Research is needed to determine the comparative effectiveness of therapies for sickle cell pain, acute neuropathic pain, neck pain, and management of postoperative pain following discharge; effects of therapies for acute pain on non-pain outcomes; effects of therapies on long-term outcomes, including long-term opioid use; and how benefits and harms of therapies vary in subgroups.
APA, Harvard, Vancouver, ISO, and other styles
9

Mark, Tami L., William N. Dowd, and Carol L. Council. Tracking the Quality of Addiction Treatment Over Time and Across States: Using the Federal Government’s “Signs” of Higher Quality. RTI Press, July 2020. http://dx.doi.org/10.3768/rtipress.2020.rr.0040.2007.

Full text
Abstract:
The objective of this study was to track trends in the signs of higher-quality addiction treatment as defined by the National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Addiction, and the Substance Abuse and Mental Health Services Administration. We analyzed the National Survey of Substance Abuse Treatment Services from 2007 through 2017 to determine the percent of facilities having the characteristics of higher quality. We analyzed the percent by state and over time. • We found improvements between 2007 and 2017 on most measures, but performance on several measures remained low. • Most programs reported providing evidence-based behavioral therapies. • Half or fewer facilities offered medications for opioid use disorder; mental health assessments; testing for hepatitis C, HIV, and sexually transmitted diseases; self-help groups; employment assistance; and transportation assistance. • There was significant state-level variation across the measures.
APA, Harvard, Vancouver, ISO, and other styles
10

Halker Singh, Rashmi B., Juliana H. VanderPluym, Allison S. Morrow, Meritxell Urtecho, Tarek Nayfeh, Victor D. Torres Roldan, Magdoleen H. Farah, et al. Acute Treatments for Episodic Migraine. Agency for Healthcare Research and Quality (AHRQ), December 2020. http://dx.doi.org/10.23970/ahrqepccer239.

Full text
Abstract:
Objectives. To evaluate the effectiveness and comparative effectiveness of pharmacologic and nonpharmacologic therapies for the acute treatment of episodic migraine in adults. Data sources. MEDLINE®, Embase®, Cochrane Central Registrar of Controlled Trials, Cochrane Database of Systematic Reviews, PsycINFO®, Scopus, and various grey literature sources from database inception to July 24, 2020. Comparative effectiveness evidence about triptans and nonsteroidal anti-inflammatory drugs (NSAIDs) was extracted from existing systematic reviews. Review methods. We included randomized controlled trials (RCTs) and comparative observational studies that enrolled adults who received an intervention to acutely treat episodic migraine. Pairs of independent reviewers selected and appraised studies. Results. Data on triptans were derived from 186 RCTs summarized in nine systematic reviews (101,276 patients; most studied was sumatriptan, followed by zolmitriptan, eletriptan, naratriptan, almotriptan, rizatriptan, and frovatriptan). Compared with placebo, triptans resolved pain at 2 hours and 1 day, and increased the risk of mild and transient adverse events (high strength of the body of evidence [SOE]). Data on NSAIDs were derived from five systematic reviews (13,214 patients; most studied was ibuprofen, followed by diclofenac and ketorolac). Compared with placebo, NSAIDs probably resolved pain at 2 hours and 1 day, and increased the risk of mild and transient adverse events (moderate SOE). For other interventions, we included 135 RCTs and 6 comparative observational studies (37,653 patients). Compared with placebo, antiemetics (low SOE), dihydroergotamine (moderate to high SOE), ergotamine plus caffeine (moderate SOE), and acetaminophen (moderate SOE) reduced acute pain. Opioids were evaluated in 15 studies (2,208 patients).Butorphanol, meperidine, morphine, hydromorphone, and tramadol in combination with acetaminophen may reduce pain at 2 hours and 1 day, compared with placebo (low SOE). Some opioids may be less effective than some antiemetics or dexamethasone (low SOE). No studies evaluated instruments for predicting risk of opioid misuse, opioid use disorder, or overdose, or evaluated risk mitigation strategies to be used when prescribing opioids for the acute treatment of episodic migraine. Calcitonin gene-related peptide (CGRP) receptor antagonists improved headache relief at 2 hours and increased the likelihood of being headache-free at 2 hours, at 1 day, and at 1 week (low to high SOE). Lasmiditan (the first approved 5-HT1F receptor agonist) restored function at 2 hours and resolved pain at 2 hours, 1 day, and 1 week (moderate to high SOE). Sparse and low SOE suggested possible effectiveness of dexamethasone, dipyrone, magnesium sulfate, and octreotide. Compared with placebo, several nonpharmacologic treatments may improve various measures of pain, including remote electrical neuromodulation (moderate SOE), magnetic stimulation (low SOE), acupuncture (low SOE), chamomile oil (low SOE), external trigeminal nerve stimulation (low SOE), and eye movement desensitization re-processing (low SOE). However, these interventions, including the noninvasive neuromodulation devices, have been evaluated only by single or very few trials. Conclusions. A number of acute treatments for episodic migraine exist with varying degrees of evidence for effectiveness and harms. Use of triptans, NSAIDs, antiemetics, dihydroergotamine, CGRP antagonists, and lasmiditan is associated with improved pain and function. The evidence base for many other interventions for acute treatment, including opioids, remains limited.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Opioid use disorder (OUP)' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography